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ABSTRACT Today’s gold standard in HIV therapy is combined antiretroviral therapy
(cART). It requires strict adherence by patients and lifelong medication, which can
lower the viral load below detection limits and prevent HIV-associated immunodeﬁ-
ciency but cannot cure patients. The bispeciﬁc T cell-engaging (BiTE) antibody tech-
nology has demonstrated long-term relapse-free outcomes in patients with relapsed
and refractory acute lymphocytic leukemia. Here, we generated BiTE antibody con-
structs that target the HIV-1 envelope protein gp120 (HIV gp120) using either the
scFv B12 or VRC01, the ﬁrst two extracellular domains (1  2) of human CD4 alone
or joined to the single chain variable fragment (scFv) of the antibody 17b fused to
an anti-human CD3 scFv. These engineered human BiTE antibody constructs
showed engagement of T cells for redirected lysis of HIV gp120-transfected CHO
cells. Furthermore, they substantially inhibited HIV-1 replication in peripheral blood
mononuclear cells (PBMCs) as well as in macrophages cocultured with autologous
CD8 T cells, the most potent being the human CD4(1  2) BiTE [termed CD(1  2)
h BiTE] antibody construct and the CD4(1  2)L17b BiTE antibody construct. The
CD4(1  2) h BiTE antibody construct promoted HIV infection of human CD4/CD8
T cells. In contrast, the neutralizing B12 and the VRC01 BiTE antibody constructs, as
well as the CD4(1  2)L17b BiTE antibody construct, did not. Thus, BiTE antibody
constructs targeting HIV gp120 are very promising for constraining HIV and warrant
further development as novel antiviral therapy with curative potential.
IMPORTANCE HIV is a chronic infection well controlled with the current cART. How-
ever, we lack a cure for HIV, and the HIV pandemic goes on. Here, we showed in
vitro and ex vivo that a BiTE antibody construct targeting HIV gp120 resulted in sub-
stantially reduced HIV replication. In addition, these BiTE antibody constructs display
efﬁcient killing of gp120-expressing cells and inhibited replication in ex vivo HIV-
infected PBMCs or macrophages. We believe that BiTE antibody constructs recogniz-
ing HIV gp120 could be a very valuable strategy for a cure of HIV in combination
with cART and compounds which reverse latency.
KEYWORDS CD8 T cells, HIV, bispeciﬁc T-cell-engaging antibodies, broadly
neutralizing antibodies, macrophages
With combined antiretroviral therapy (cART), most HIV patients experience areduction in viral load below detection limits, shifting the HIV infection from a
deadly disease toward a chronic infection. However, cART-based therapies are not
curative, are dependent on strict adherence, expose patients to risk of long-term cART
toxicity, and burden the health care systems with intensive costs due to lifelong
Received 23 March 2018 Accepted 19 April
2018
Accepted manuscript posted online 2 May
2018
Citation Brozy J, Schlaepfer E, Mueller CKS,
Rochat M-A, Rampini SK, Myburgh R, Raum T,
Kufer P, Baeuerle PA, Muenz M, Speck RF. 2018.
Antiviral activity of HIV gp120-targeting
bispeciﬁc T cell engager antibody constructs. J
Virol 92:e00491-18. https://doi.org/10.1128/JVI
.00491-18.
Editor Frank Kirchhoff, Ulm University Medical
Center
Copyright © 2018 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Markus Muenz,
mmuenz@amgen.com, or Roberto F. Speck,
Roberto.speck@usz.ch.
J.B. and E.S. are co-ﬁrst authors. M.M. and R.F.S.
contributed equally to this work.
VACCINES AND ANTIVIRAL AGENTS
crossm
July 2018 Volume 92 Issue 14 e00491-18 jvi.asm.org 1Journal of Virology
 o
n
 July 12, 2018 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
treatment necessity. Studies on elite controllers demonstrated the critical role of the T
cell response in the control of acute and chronic HIV-1 infection (1) Therefore, an
attempt to improve the patients’ cellular responses against HIV has emerged as a
promising cure strategy. Indeed, genetically manipulated primary CD8 T cells, ex-
pressing a chimeric antigen (Ag) receptor speciﬁc for the HIV gp120, effectively lysed
HIV-infected CD4 T cells in vitro (2). As an alternative to gene-engineered HIV-speciﬁc
T cells, the BiTE technology (AMGEN, Inc.) redirects the cytotoxic potential of any T cell
to the target cell expressing the corresponding antigen.
The BiTE approach has already been successfully applied in the clinic in patients
suffering from non-Hodgkin’s lymphoma or B-cell lymphoblastic leukemia (3, 4). In-
deed, the FDA-licensed BiTE blinatumomab (Blincyto), targeting CD19 cells results in
shrinking of neoplastic lymph nodes (5) and in clearing bone marrow of blasts in those
patients (6), respectively. Several other BiTE candidates are under clinical investigation
in solid tumor indications, for example, AMG212/BAY2010112, which targets the
prostate-speciﬁc membrane antigen (7), and MEDI-565/AMG211, which targets the
carcinoembryonic antigen (8, 9).
In 1991, Traunecker and Berg independently published bispeciﬁc antibody con-
structs based on domains of the natural HIV receptor CD4 and an anti-CD3 binding
moiety (10, 11). Shortly after, Okada et al. presented a novel bifunctional antibody
consisting of a Fab part to HIV gp120 and anti-CD3 (12). All those bispeciﬁc antibody
constructs showed in vitro lysis of HIV-infected T cell lines. Apart from work by Chamow
et al. (13), who generated a bispeciﬁc antibody similar to the ones by Traunecker et al.
and Berg et al., no further development of this concept took place for more than 20
years. In 2015, bispeciﬁc antibody constructs based on antibody fragments targeting
HIV gp120 and CD3 were described to be active in vitro using patient samples (14, 15).
To further elucidate the naturally given broad potential of HIV gp120 as a target
binding domain, here we generated BiTE antibody constructs by fusing either (i) the
N-terminal domains 1 and 2 of human CD4 [CD4(1  2)], (ii) the scFv of broadly
neutralizing antibody (bNAb) B12 or VRC01, or (iii) the human CD4(1  2), linked to the
scFv of 17b (CD4L17b), to our proprietary human anti-human CD3 scFv.
RESULTS
The human BiTE antibody constructs binding to HIV gp120-transfected cells
resulted in redirected lysis using unstimulated PBMC or stimulated CD8 T cells.
The two N-terminal domains of human CD4, the natural receptor for HIV, were fused to
the proprietary human anti-human CD3 scFv (Fig. 1A). This BiTE antibody construct
separated very clearly CHO cells expressing the HIV gp120 of either the CXCR4-tropic
strain, HXB2, or the CCR5-tropic strain, SF-162, from parental ones using ﬂow cytometry
(Fig. 1B).
To demonstrate the binding speciﬁcity of the two N-terminal domains of human
CD4 for HIV-infected human T cells, the anti-CD3 domain from the human CD4(1  2)
BiTE [CD4(1  2) h BiTE] was replaced by a murine counterpart, CD4(1  2) m BiTE,
which does not recognize human CD3. As expected, binding of HIV gp120 on HIV T
cells by the CD4(1  2) m BiTE occurred independently of binding to human CD3; in
fact, HIV p24 cells were bound by the CD4(1  2) m BiTE (Fig. 1C). These data with H9
cells clearly show that the BiTEs via the two N-terminal CD4 domains recognize and
bind gp120 in cells infected with replication-competent HIV that approximates the in
vivo situation more closely than data obtained with CHO cells genetically comple-
mented with gp120. Notably, CHO cells of Chinese hamster origin are not per se
permissive to HIV replication.
The BiTE antibody constructs redirected lysis of HIV gp120-transfected CHO cells
when cocultured with prestimulated human CD8 T cells in the pico- or low-
nanomolar range (Fig. 1D). The other BiTE antibody constructs generated were
equally cytotoxic in this assay (Fig. 1E). Untransfected CHO cells were not lysed
when incubated with CD4(1  2) h BiTE and effector cells, proving the speciﬁcity of
the BiTE antibody construct (Fig. 1D).
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FIG 1 Various human BiTE antibody constructs are highly cytotoxic to HIV env gp120-expressing CHO cells when cocultured with CD8 T cells. (A) Cartoon
of the various BiTE antibody constructs generated. The ﬁrst two N-terminal domains (1  2) of human CD4 (dark gray/black) are linked by a glycine/serine
(Continued on next page)
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The human BiTE antibody constructs showed a dose-dependent inhibition of
HIV replication in ex vivo HIV-infected PBMCs and monocyte-derived macro-
phages (MDMs) cocultured with CD8 T cells. Prestimulated PBMCs were infected
with HIVNL4-3 and subsequently incubated with different concentrations of the various
BiTE antibody constructs. All BiTE antibody constructs speciﬁcally targeting HIV gp120
showed a dose-dependent inhibition of HIV replication (Fig. 2A and B). The CD4(1  2),
CD417b, and B12 BiTE antibody constructs were the most potent ones, with 90% HIV
inhibition at 1 g/ml; the CD417b BiTE antibody construct showed90% HIV inhibition
at 0.1 g/ml. The effective inhibitory concentration 50 (IC50) was 0.048 g/ml for the
CD4(1 2) h BiTE, 0.037 g/ml for the CD417b BiTE, 0.0038 g/ml for the B12 BiTE, and
2.86 g/ml for the VRC01 BiTE. The CD4(1  2) m BiTE also showed antiviral activity at
10 g/ml, while at lower dosage it had a rather pro-HIV effect (Fig. 2B).
The viral resistance (Vres) to inhibition by maximal BiTE concentrations was also
most prominent for the BiTE antibody constructs comprising the human CD4 domains
1 and 2 alone or coupled to the scFv 17b [percent (averages  standard deviations)
replication compared to the normalized control: human BiTE, 1.02  0.31; CD4(1 
2)L17b, 0.73  0.4; VRCO1, 42.2  30.8; B12, 1.34  0.52; CD4(1  2) murine BiTE,
6.4  5.5].
The HIV inhibition was paralleled by a preservation of CD4 T cells and expansion
of CD8 T cells (Fig. 3A and B). Under the condition tested, the BiTE antibody constructs
with the CD4 domains were the most beneﬁcial ones for the preservation of CD4 T
cells.
We observed very similar anti-HIV effects between HIV-infected cocultures of MDMs
and autologous CD8 T cells by the various BiTE antibody constructs and HIV-infected
PBMCs. The BiTE antibody constructs comprising the CD4 domains excelled in their
anti-HIV activity (Fig. 4A and B) with, at the limit, detectable HIV replication as judged
by the Vres [percent (averages  standard deviations) replication compared to nor-
malized control: CD4(1 2) human BiTE, 0.75 0.2; CD4(1 2)L17b, 3.3 0.6; VRCO1,
4  1.6; B12, 10.75  5.64; CD4(1  2) murine BiTE, 24.2  1.8]. As expected, the BiTE
antibody constructs lost their anti-HIV effects in HIV-infected MDMs without the
addition of CD8 T cells (Fig. 4C).
We again observed some anti-HIV activity with the CD4(1 2) murine BITE antibody
construct but much less than that with the human counterpart. The HIV inhibition
observed with the murine BiTE antibody construct points to the pure neutralization
activity by the CD4 domains 1 and 2 as opposed to the human BiTE; notably, the scFv
targeting the murine CD3 has no cross-reactivity to human CD3.
CD4(1  2) h BiTE led to HIV infection of CD4/CD8 T cells with the CXCR4-
tropic strain NL4-3. We know that soluble CD4 as well as CD4 presented in trans by
another cell may promote a conformational change of the HIV gp120, resulting in
infection of CD4 cells. Thus, we wanted to exclude that the CD4(1  2) h BiTE
promotes HIV infection of CD4 T cells. However, we found that CD4(1  2) h BiTE
treatment of isolated CD8/CD4 T cells resulted in a higher p24 level than in the
controls when using spinoculation. Notably, pretreatment with the CD4(1  2)17b-,
B12-, and VRC01-based BiTE antibody constructs showed HIV p24 levels comparable to
those of cells solely challenged with HIV (Fig. 5). Thus, only the CD4(1  2) BiTE
antibody construct resulted in HIV infection of CD4/CD8 cells, pointing to its speciﬁc
property to induce conformational changes of gp120, which in turn enables HIV to
infect CD4 T cells.
FIG 1 Legend (Continued)
linker (G4S) to a proprietary anti-human CD3 scFv (gray/white). Variable domains within an scFv are linked by a (G4S)3 linker. (B) Fluorescence-activated cell
sorting (FACS) binding of the CD4(1  2) h BiTE antibody construct (green) and mouse anti-histidine tag MAb plus goat anti-mouse Fc MAb-phycoerythrin
(PE) staining control (black) on HIV gp120 (HXB2/SF162)-transfected CHO cells. (C) Staining of HIVIIIB H9 T cells versus HIV H9 T cells using the CD4(1 
2)m BiTE. BiTE signal was measured using mouse anti-histidine MAb, followed by goat anti-mouse Fc MAb-PE. Fixed and lysed cells were stained using a
mouse anti-HIV p24 MAb-allophycocyanin. (D and E) Prestimulated puriﬁed human CD8 T cells were incubated with HIV gp120-transfected CHO cells (E:T
ratio, 10:1) and BiTE dilution series of the CD4(1  2)h BiTE (green) BiTE versus irrelevant (irr.) control BiTE antibody construct (black) (D) or various BiTE
antibody constructs (E).
Brozy et al. Journal of Virology
July 2018 Volume 92 Issue 14 e00491-18 jvi.asm.org 4
 o
n
 July 12, 2018 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
DISCUSSION
Here, we present the anti-HIV potency of BiTE antibody constructs with either
CD4 domains 1 and 2, neutralizing scFv against gp120, or both together (Fig. 1A).
All BiTE antibody constructs showed promising potency in constraining HIV repli-
cation in ex vivo HIV-infected PBMCs or MDMs cocultured with autologous CD8 T
cells. The CD4(1  2) human BiTE antibody construct resulted in very low levels
infection of CD4 cells, prohibiting its clinical use. Notably, CD417b was the most
potent BiTE antibody construct in a head-to-head comparison and did not show this
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disturbing infection of CD4 cells. Thus, this genre of BiTE is very promising for treating
HIV and potentially also for targeting latently HIV-infected cells in a shock-and-kill
approach.
We ﬁrst veriﬁed the speciﬁcity of the CD4(1 2) human BiTE for binding HIV gp120:
it bound ﬁrmly the HIV gp120 expressed on CHO cells irrespective of gp120’s corecep-
tor selectivity (Fig. 1B). Furthermore, we found a correlation between the binding of the
chimeric CD4(1  2) murine BiTE and intracellular HIV p24 Ag expression in HIVIIIB-
infected H9 cells, pointing to CD4 domain speciﬁcity for HIV-infected cells; uninfected
H9 cells did not bind the CD4(1 2) murine BiTE (Fig. 1C). The partial overlap observed
between p24 Ag-positive and gp120-positive cells is a well-known phenomenon and is
explained by a time-wise differential expression of HIV proteins. The CD4(1 2) human
BiTE displayed its cytotoxicity on HIV gp120 CHO cells when cocultured with CD8 T
cells. No cytotoxicity was observed with parental CHO cells (Fig. 1D). Furthermore, the
A)
SS
C
Lymphocytes
57.3
0 20K 40K 60K
0
20K
40K
60K 5.88 0.62
66.227.3
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
54.9 2.24
27.115.7
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
NL4-3uninfected
C
D
4+
 T
-c
el
ls
CD8+ T-cellsFSC
45.8 39.7
7.726.74
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD4(1+2)L17b 
human BiTE   
33.3 3.13
53.210.4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
VRC01 human BiTE
24.3 3.34
62.79.63
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
B12 human BiTE
65.6 1.95
22.89.68
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD4(1+2) murine BiTE
53.5 41.3
1.214.05
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD4(1+2) human BiTE
C
D
4+
 T
-c
el
ls
CD8+ T-cells
B)
%
C
D
8+
 T
-c
el
ls
0
20
40
60
80
***
***
***
0
20
40
60
80
****
***
***
%
C
D
4+
 T
-c
el
ls
C
D
4+
/C
D
8+
 T
-c
el
l r
at
io
0.01
0.1
1
10
**
**
Un
inf
ec
ted
NL
4-3
 (N
o B
iTE
)
CD
4(1
+2
) h
um
an
 B
iTE
VR
C0
1 h
um
an
 B
iTE
B1
2 h
um
an
 B
iTE
CD
4(1
+2
)L1
7b
 hu
ma
n B
iTE
CD
4(1
+2
) m
ur
ine
 B
iTE
Un
inf
ec
ted
NL
4-3
 (N
o B
iTE
)
CD
4(1
+2
) h
um
an
 B
iTE
VR
C0
1 h
um
an
 B
iTE
B1
2 h
um
an
 B
iTE
CD
4(1
+2
)L1
7b
 hu
ma
n B
iTE
CD
4(1
+2
) m
ur
ine
 B
iTE
Un
inf
ec
ted
NL
4-3
 (N
o B
iTE
)
CD
4(1
+2
) h
um
an
 B
iTE
VR
C0
1 h
um
an
 B
iTE
B1
2 h
um
an
 B
iTE
CD
4(1
+2
)L1
7b
 hu
ma
n B
iTE
CD
4(1
+2
) m
ur
ine
 B
iTE
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FIG 4 Dose-dependent inhibition of HIV replication by the human BiTE antibody constructs tested in
ex vivo HIV-infected MDMs cocultured with autologous CD8 T cells. (A) MDMs were infected overnight
(Continued on next page)
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data observed with H9 cells nicely demonstrate that the BiTE antibody constructs
recognize and bind gp120 when naturally expressed in the context of a productive
infection. Notably, productive infection results in a markedly lesser expression of gp120
than the one we had in the CHO cells genetically complemented with gp120, which
speaks in favor of the high binding afﬁnity of the two N-terminal domains of CD4 to
gp120.
Since a BiTE comprising solely the CD4 domains may result in trans-infection of
CD4-negative cells (16), we created additional BiTE antibody constructs combining the
CD4 domains 1 and 2 with an scFV against HIV env gp120 or BiTE antibody constructs
with an scFv against gp120 alone. The scFv were based on the 17B antibody, which
binds to a CD4-induced antibody epitope (17), and on the VRCO1 or B12 binding site
antibodies (18). These BiTE antibody constructs showed cytotoxicity against HIV
gp120 CHO cells cocultured with CD8 T cells comparable to that of the human
CD4(1  2) BiTE (17). All of the BiTE antibody constructs but the murine one showed
a clear dose-dependent inhibition of HIV replication in ex vivo HIV-infected PBMCs as
well as MDMs cocultured with autologous CD8 T cells over time; in fact, the CD4(1 
2) human BiTE as well as the CD417b BiTE were the most potent BiTE antibody
constructs overall. In PBMCs at the highest dose tested and in MDMs cocultured with
CD8 T cells, even at all doses tested, the CD4(1  2) murine BiTE displayed some
anti-HIV activity but much less than that of its human counterpart. This blocking effect
occurs most likely via binding gp120 and is reminiscent of work showing virus neu-
tralization by administering soluble CD4 domains (19). Notably, CD8 T cells were
mandatory for deploying the BiTE antibody constructs’ anti-HIV activity in macrophages
FIG 4 Legend (Continued)
with the CCR5-tropic strain YU-2 and subsequently cocultured with autologous puriﬁed CD8 T cells,
and the corresponding BiTE antibody constructs in dilution series were added. HIV replication was
monitored by quantifying p24 Ag in the supernatant over time (n  3 in triplicates). (B) Compilation
of the dose-dependent anti-HIV activity of all BiTE antibody constructs. (C) The human BiTE antibody
constructs deploy their anti-HIV activities in ex vivo-infected MDMs only when cocultured with CD8
T cells.
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FIG 5 HIV replication in primary unstimulated CD4/CD8 T cells incubated with BiTE antibody
constructs prior to HIV infection via spinoculation. The generated BiTE antibody constructs were
incubated with primary CD8 T cells prior to infection with NL4-3 or YU-2 via spinoculation. After
washing and 7 days of incubation, the viral replication was determined by quantifying HIV p24 in the
cell culture supernatant. The assay was performed using three independent donors in triplicates
(averages  SEM are shown). Statistics were calculated using ANOVA followed by Tukey’s multiple-
comparison test.
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(Fig. 4C). As we puriﬁed CD8 T cells using a CD8 microbead assay, we had a small
number of CD8 NKT cells in addition to CD8 T cells in the cocultures of MDMs and
CD8 T cells. To what extent they contributed to the antiviral effect observed remains
unknown. Notably, the antiviral effects of the BiTE antibody constructs went along
with a preservation of the CD4/CD8 T-cell ratio.
The idea of bispeciﬁc antibodies retargeting T cells to constrain HIV has been around
since the early nineties of the last century (10–13). In 2015, Sung et al. and Sloan et al.
revived this idea by designing dual-afﬁnity retargeting proteins comprising novel
broadly neutralizing or nonneutralizing gp140 HIV antibodies (14, 15, 20). Notably, the
CD4(1  2) human BiTE had a design, with the two N-terminal CD4 domains targeting
gp120, similar to that of some of the older constructs (10–13). All the constructs
reported had a very efﬁcient cytotoxic activity against cells expressing HIV env gp120.
The design of the constructs differs and most likely explains subtle differences in their
antiviral potency. For example, we observed a very potent antiviral activity with the
VRCO1 BiTE antibody construct, while Sloan et al. did not (15). Sloan et al. and Pegu et
al. also showed that these retargeting molecules reverse HIV latency and lead to a
decrease of the HIV latent reservoir (15, 20).
Similarly to plain broadly neutralizing antibodies, HIV may escape bispeciﬁc anti-
bodies. Thus, there is a theoretical advantage of the human CD4(1  2) BiTE, since its
efﬁcacy is independent of the HIV gp120 sequence, i.e., the CD4(1  2) BiTE should be
active as long as there is CD4-dependent HIV entry. It remains highly unlikely that one
single bNAb will be sufﬁcient to suppress HIV replication completely and prevent
escape mutations (21). A potential downsize of the CD4(1  2) h BiTE antibody
construct is its potential to mediate infection of CD4/CD8 T cells, as seen in the ex
vivo experiment with HIV spinoculated PBMCs. Spinoculation is widely used in virology
research to enhance viral infection. Spinoculation is coupled with spin-induced cyto-
skeletal dynamics that promote receptor mobilization, viral entry, and postentry pro-
cesses (22). Thus, spinoculation-induced cellular permissiveness may be beyond the
natural capacity of an infecting virus, and thus the data we generated of HIV infection
of CD4/CD8 T cells need to be interpreted with caution.
While theoretically at least the CD4(1  2) h BiTE may trigger conformational
changes on HIV gp120, allowing for HIV coreceptor binding and subsequent infection
of CD4 cells (16, 23), the HIV gp120 neutralizing antibodies, such as B12 and VRC01,
lock HIV gp120 prior to any conformational changes. In contrast, the scFv 17b targets
a CD4-inducible HIV env gp120 epitope. Thus, the dual-targeting BiTE, CD417b BiTE,
combines two very nice features, i.e., binding HIV env gp120 independent of its
sequence via the two N-terminal CD4 domains, resulting in the exposure of the
CD4-inducible epitope, which then will be accessible to the scFv 17b. This dual-
targeting BiTE also prevented the CD4-dependent infection and therefore seems a
promising approach to design broad and highly anti-HIV active BiTE antibody con-
structs. Notably, the 17b scFv might also enhance the speciﬁcity of a CD4(1  2)-based
BiTE with respect to CD4-insensitive HIV strains (24). BiTE antibody constructs compris-
ing the scFv of broadly neutralizing monoclonal antibody (MAb) B12 or VRC01 also
show no induction of HIV infection but are prone to HIV mutational immune escape.
Clearly, we do not know to what extent the phenomenon of BiTE-mediated HIV
infection of CD4/CD8 cells is clinically relevant.
CD3-dependent internalization (25) of a BiTE that is bound to CD3 and to an HIV
virion represents another potential mechanism of CD4-independent HIV infection. As
HIV p24 levels are not increased in CD8 T cells incubated with CD417b-, B12-, or
VRC01-based BiTE antibody constructs compared to cells incubated with the control
BiTE, potential uptake of virions probably does not occur, or if it occurs, virions will be
degraded, not leading to productive infection.
Redirecting T cells to lyse HIV-infected cells warrants further development using the
clinically validated BiTE platform technology. Since CD3/interleukin-2 (IL-2)-stimulated
T cells increased viral replication in a small number of patients (26) and efﬁciently killed
reactivated, latently infected CD4 T cells in vitro (27), T cell-engaging BiTE antibodies
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via binding to the CD3 receptor could also reactivate viral replication in latently
infected cells and subsequently induce their lysis, as discussed above (15, 20). Another
approach of an anti-HIV-directed cytotoxic therapy was recently described in HIV BLT
mice treated with an antibody-drug conjugate in addition to cART (28). Under ideal
circumstances, BiTE antibodies might show curative potential, as has been demon-
strated in prolonged relapse-free survival of leukemia patients (29).
In summary, the BiTE antibody constructs described redirected T cells to HIV gp120
cells and inhibited viral replication in vitro. Notably, T-cell activation promotes viral
replication in patients (26) and is also able to reverse HIV latency (27); thus, these BiTE
antibody constructs could likewise mediate viral replication in latently infected cells via
their activation, eventually resulting in their cell death. They might be especially
valuable in patients with cART for eliminating the latent reservoir. cART in this scenario
would in any case prevent spreading infection in the case of the unfortunate possibility
of CD4-independent infection. Other T cell-engaging, bispeciﬁc antibodies, which bind
to HIV gp120, also gave very promising data similar to ours (14, 15). Apart from the
discussed bispeciﬁc antibodies, a rather impressive number of bispeciﬁc antibodies of
any kind have been published in the ﬁeld of HIV over the last couple of years, including,
among others, bispeciﬁc antibodies for increasing the breadth and strength for neu-
tralizing HIV gp120 (30) or bispeciﬁc antibodies recruiting NK cells for killing HIV-
infected cells (31, 32). Thus, bispeciﬁc antibody constructs overall warrant further
investigation for their potential to eliminate the HIV latent reservoir, preferentially in
vivo using either humanized mice or nonhuman primate models. As of now, no clinical
trials are registered on the ClinicalTrials.gov website.
MATERIALS AND METHODS
Cell lines. Dihydrofolate reductase (DHFR)-deﬁcient CHO cells were grown in suspension in a
humidiﬁed incubator at 37°C and 5% CO2 with HyQ LS medium (HyClone, Logan) supplemented with 100
U/ml penicillin and 100 g/ml streptomycin. For recombinant HIV envelope expression in CHO cells, the
sequences of the extracellular domains of HIV HXB2 and HIV SF162 were fused to the transmembrane
and intracellular domain of the human epithelial cell adhesion molecule (EpCAM; amino acids [aa] 266
to 314) using the pEF DHFR plasmid, and selection of transfected cells expressing HXB2 or SF162 was
achieved by using nucleoside-free medium. The HPB-ALL cells (human T cell line) and the HIV and HIV
H9 cells (HIV IIIB H9 T cells [HIV] and the H9 T cells [HIV]; human T cell line) were grown in RPMI
medium (Biochrom) supplemented with 10% fetal calf serum, 500 nM -mercaptoethanol (Gibco), 100
U/ml penicillin, 100 g/ml streptomycin, 1 mM sodium pyruvate, 1 nonessential amino acids, and 10
mM HEPES (RPMI complete medium; Biochrom).
Primary cells. PBMCs obtained from the local blood bank or from healthy volunteers were Ficoll
isolated and incubated in RPMI medium supplemented with 10 U/ml IL-2, 1% glutamine, and 1%
penicillin. For the determination of BiTE activity, prestimulated CD8 T cells were used as effector
cells and CHO gp120 cells as target cells. Prestimulated CD8 T cells were isolated from PBMCs
stimulated by anti-CD3 and anti-CD28 antibodies (1 g/ml) coated on a petri dish and 20 U/ml IL-2
for 72 h, followed by an additional 24 h in a ﬂask containing fresh medium and 20 U/ml IL-2. CD8
T cells then were negatively isolated via magnetic cell labeling using microbeads (Miltenyi). To
generate monocyte-derived macrophages (MDMs), monocytes were isolated using CD14 microbeads
(catalog no. 130-050-201; Miltenyi), seeded at a cell count of 1.5  105 per cm2, and cultured in RPMI
1640 medium (BioWhittaker) supplemented with 10% human type AB serum (catalog no. H1513;
Sigma), 2 mM L-glutamine, 1% penicillin-streptomycin, and 10 ng/ml M-CSF for 6 days. At this time
point, medium was replaced with medium without cytokines and cultured for another 2 days.
Construction and production of BiTE antibody constructs. The human CD4 protein domains 1 and
2 (CD4 aa 26 to 207) were fused to the proprietary anti-human CD3 or anti-mouse CD3 scFv by SG4S
linker. In case of the CD417b h BiTE, the CD4 domains 1 and 2 are linked by a (G4S)8 sequence to the
scFv of MAb 17b [VL/VH order, linked by (G4S)3], which is fused to the anti-CD3 scFv. The scFv of MAbs
B12 and VRC01 [in VH/VL order, linked by (G4S)3 linker] are likewise fused to the anti-human CD3 scFv.
The target binding moieties were inserted in frame into a DHFR plasmid encoding a eukaryotic signal
peptide for expression of the BiTE antibody constructs into the cell culture supernatant and a C-terminal
histidine tag for protein puriﬁcation and detection. A sequence-veriﬁed clone was used to transiently
transfect HEK 293 F cells using 293-free transfection reagent (Novagen Inc.) for 72 h according to the
manufacturer. The cell culture supernatant was ﬁltered (0.2 m) and stored at 20°C until puriﬁcation.
Proteins were puriﬁed by immobilized metal afﬁnity chromatography (Fractogel loaded with ZnCl2) and
eluted by 500 mM imidazole, followed by a concentration step and subsequent size exclusion chroma-
tography in 10 mM citrate–75 mM lysine buffer as described by Kufer et al. (33). BiTE antibody construct
monomers were collected and stored at 80°C.
Determination of in vitro cytotoxicity using HIV gp120-transfected CHO cells. HIV gp120-
transfected CHO cells were used as target cells for in vitro cytotoxicity assays. Human PBMCs were
Brozy et al. Journal of Virology
July 2018 Volume 92 Issue 14 e00491-18 jvi.asm.org 10
 o
n
 July 12, 2018 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
isolated from blood of healthy volunteers by Ficoll (Biochrom) density gradient centrifugation using
standard procedures. For the stimulated cytotoxicity assay, human PBMCs were stimulated by immobi-
lized CD3 antibody (OKT-3; Janssen-Cilag), immobilized CD28 antibody (BD), and recombinant IL-2 (20
U/ml). After centrifugation, cells were washed with phosphate-buffered saline (PBS) solution and
resuspended in RPMI 1640 complete medium. For chromium release assays with the various BiTE
antibody constructs, target cells were labeled by incubation with approximately 7 MBq 51Cr for 1 h,
followed by removal of free chromium with two washing steps and resuspension in RPMI 1640 complete
medium (Gibco). T cells and labeled target cells were adjusted to an effector-to-target (E:T) ratio of 10:1.
One hundred microliters of this suspension was transferred to each well of a 96-well plate preﬁlled with
one hundred microliters of BiTE dilution or medium in the case of background controls. The BiTE
antibody-mediated cytotoxic reaction proceeded for 18 h at 37°C in a 5% CO2 humidiﬁed incubator. After
incubation, 100 l of each well was removed, and cytotoxicity was measured as relative values of
released chromium in the supernatant relative to the difference of maximum lysis (determined by
addition of Triton X-100) and spontaneous lysis (in the absence of effector cells). All measurements were
done in quadruplicate. Measurement of 51Cr activity in the supernatants was performed with a Wizard
3 -counter (Perkin-Elmer). For the CD4(1  2) h BiTE, target cells were labeled using Vybrant DiD (Life
Technologies) dye as instructed by the manufacturer. Effector and target cells were adjusted and added
to BiTE dilution or medium as described above. After the incubation period, cells were washed in PBS,
stained with propidium iodide (PI; Sigma), and analyzed by ﬂow cytometry for PI-positive/DiD-labeled
target cells. Speciﬁc cytotoxicity was calculated using the formula (1  viable cells [BiTE dilution]/viable
cells [no BiTE control]) 100. Data were plotted using sigmoidal dose-response ﬁtting in GraphPad Prism
7.04.
HIV infection of primary cells. The virus was generated by transfection of 293 T cells with proviral
DNA from NL4-3 (p24 for the viral stock, 85 ng/ml) or YU-2 (30 ng/ml). PBMCs were infected overnight
with supernatant diluted 1:3.
Coincubation of BiTE antibody constructs with HIV-infected PBMCs. A total of 105 PBMC were
incubated in 200 l RPMI medium and incubated for 12 days with dilutions of the indicated BiTE
antibody construct. On days 5, 8, and 12 postinfection (p.i.), 50 l of the cell culture supernatant was
sampled and replenished for further incubation. Aliquots of the cell culture supernatant were diluted for
a ﬁnal concentration of 1% Empigen detergent and stored at 20°C for later analysis. The HIV p24
antigen (Ag) levels were determined by a sandwich enzyme-linked immunosorbent assay (ELISA) as
described by Moore et al. (34).
Coincubation of BiTE antibody constructs with HIV-infected MDMs cocultured with CD8 T
cells.We ﬁrst infected 5 104 MDMs overnight with YU-2, washed the MDMs extensively in the morning,
and then added 2 105 autologous CD8 cells together with the various BiTE antibody constructs to the
coculture. Subsequently, we monitored HIV replication by quantifying the p24 Ag in the supernatant over
time. In a subsequent experiment, we also compared the anti-HIV potential of the BiTE antibody
constructs generated in ex vivo HIV-infected MDMs with or without CD8 T cells. In these assays, we used
puriﬁed CD8 T cells, which we isolated using the MACS human CD8 microbeads assay from Miltenyi
Biotech (130-045-201).
Flow cytometry. Binding of BiTE antibody constructs (10 g/ml) was visualized by a murine
antihistidine antibody (10 g/ml; AbD Serotec) and a ﬂuorescently labeled anti-mouse Fc antibody (5
g/ml; Jackson ImmunoResearch). Intracellular p24 was detected using a commercially available HIV gag
p24 antibody (Kc57) (Beckman Coulter). We quantiﬁed the number of CD8 T cells with the anti-CD8
antibody Brilliant Violet 421 anti-human CD8a antibody from BioLegend (301036).
BiTE-mediated infection assay of CD4/CD8 T cells. Unstimulated human CD8 T cells were
negatively isolated using microbeads after Ficoll puriﬁcation and subsequently incubated with the
indicated BiTE antibody construct (10 g/ml) for 2 h. After washing with PBS, CD8 T cells were
challenged by spinoculation with HIV NL4-3 for 2 h, followed by washing and subsequent incubation in
RPMI medium. Cell culture supernatants on day 7 p.i. were analyzed for HIV p24 Ag.
Statistics. Statistical signiﬁcance was calculated using GraphPad Prism, version 7.04, for Windows
(www.graphpad.com; GraphPad Software, La Jolla, CA). The various test statistics used are described in
the legends to the ﬁgures.
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